A Microdose Evaluation Study of ABY-029 in Primary Sarcoma
Status:
Completed
Trial end date:
2020-12-10
Target enrollment:
Participant gender:
Summary
The primary study objective is to determine if microdoses of ABY-029 (up to 6X) lead to
detectable signals (defined as signal-to-noise ratio, SNR ≥10, with the Odyssey NIR scanner
in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining and
compare SNR to tissues with an EGFR pathology score < 1).
The secondary study objective is to assess if the spatial patterns of EGFR expression
correlate with the tumor targeting of ABY-029 detection by NIR scanner relative to
histopathology diagnosis, and other indicators (e.g. proliferation, infiltration, etc.) as
the gold standard, and to measure the molecular uptake and concentration of ABY-029 in
resected specimens.